Neumora Therapeutics (NMRA)


Market Price (11/18/2026): $0.329 | Market Cap: $62.1 MilSector: Health Care | Industry: Biotechnology

Neumora Therapeutics (NMRA)


Market Price (11/18/2026): $0.329
Market Cap: $62.1 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more.

Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -165%

Penny stock
Mkt Price is 0.3

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -187 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -312%

High stock price volatility
Vol 12M is 132%

Key risks
NMRA key risks include [1] the pivotal Phase 3 trial failure of its lead candidate, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -165%
3 Penny stock
Mkt Price is 0.3
4 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -187 Mil
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -312%
7 High stock price volatility
Vol 12M is 132%
8 Key risks
NMRA key risks include [1] the pivotal Phase 3 trial failure of its lead candidate, Show more.

NMRA in ETFs

Weight = NMRA's share of each fund

VTI0.00%
IWM0.00%
IWO0.00%
IBB0.00%
VTWO0.00%
SCHA0.00%
VHT0.00%
DFAS0.00%
+1 more covered ETF

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 17: down 9.5% in one day (S&P 500 down 1.0%)
The stock fell following its November 16 report of Third Quarter 2026 financial results and business update, including an IND application submission for NMRA-215. Slower retail sales also dragged on the market on November 17.

Down 41.4% since its Nov 3 high (S&P 500 down 2.9%)
The stock fell over this period amid general market weakness. Major declines occurred on November 5 without company news, and on November 16 and 17 following its Third Quarter 2026 financial results and IND application submission.

Show more
Prices as of 11/17/2026

Nov 17: down 9.5% in one day (S&P 500 down 1.0%)
The stock fell following its November 16 report of Third Quarter 2026 financial results and business update, including an IND application submission for NMRA-215. Slower retail sales also dragged on the market on November 17.

Down 41.4% since its Nov 3 high (S&P 500 down 2.9%)
The stock fell over this period amid general market weakness. Major declines occurred on November 5 without company news, and on November 16 and 17 following its Third Quarter 2026 financial results and IND application submission.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -79.2% change in NMRA stock from 7/31/2026 to 11/17/2026 was primarily driven by a -4.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611172026Change
Stock Price ($)1.610.33-79.2%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)180188-4.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
NMRA-79.2% 
Market (SPY)-1.7%16.6%
Sector (XLV)14.4%30.1%

Fundamental Drivers

The -86.5% change in NMRA stock from 4/30/2026 to 11/17/2026 was primarily driven by a -10.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611172026Change
Stock Price ($)2.470.33-86.5%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)169188-10.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
NMRA-86.5% 
Market (SPY)2.4%3.2%
Sector (XLV)27.9%21.4%

Fundamental Drivers

The -88.9% change in NMRA stock from 10/31/2025 to 11/17/2026 was primarily driven by a -13.9% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511172026Change
Stock Price ($)3.020.33-88.9%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)162188-13.9%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
NMRA-88.9% 
Market (SPY)8.5%9.4%
Sector (XLV)30.6%21.1%

Fundamental Drivers

The -96.9% change in NMRA stock from 10/31/2023 to 11/17/2026 was primarily driven by a -19.1% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202311172026Change
Stock Price ($)10.920.33-96.9%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)152188-19.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
NMRA-96.9% 
Market (SPY)81.6%17.6%
Sector (XLV)56.4%18.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
NMRA Return--5%-38%-83%-81%-98%
Peers Return-38%20%13%-7%37%2%9%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
NMRA Win Rate--50%42%33%27% 
Peers Win Rate48%55%47%50%60%44% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
NMRA Max Drawdown----56%-94%-91% 
Peers Max Drawdown-53%-42%-36%-35%-38%-36% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: AXSM, NBIX, JAZZ, ACAD, DNLI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventNMRAS&P 500
2025 US Tariff Shock
  % Loss-62.9%-18.8%
  % Gain to Breakeven169.9%23.1%
  Time to Breakeven64 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-40.7%-9.5%
  % Gain to Breakeven68.6%10.5%
  Time to Breakeven71 days24 days

Compare to AXSM, NBIX, JAZZ, ACAD, DNLI

In The Past

Neumora Therapeutics's stock fell -62.9% during the 2025 US Tariff Shock. Such a loss loss requires a 169.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventNMRAS&P 500
2025 US Tariff Shock
  % Loss-62.9%-18.8%
  % Gain to Breakeven169.9%23.1%
  Time to Breakeven64 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-40.7%-9.5%
  % Gain to Breakeven68.6%10.5%
  Time to Breakeven71 days24 days

Compare to AXSM, NBIX, JAZZ, ACAD, DNLI

In The Past

Neumora Therapeutics's stock fell -62.9% during the 2025 US Tariff Shock. Such a loss loss requires a 169.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Neumora Therapeutics (NMRA)

Neumora Therapeutics (NMRA) Business Description

Neumora Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing the global crisis in brain diseases, encompassing a wide range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company differentiates itself by employing a "precision neuroscience" approach to drug development. This involves building a diversified therapeutic pipeline focused on novel mechanisms of action and leveraging its proprietary "Precision Toolbox," which integrates machine learning algorithms, translational tools, and patient data insights. This strategy aims to better understand the biological drivers of these complex and heterogeneous disorders, identify targeted patient populations, optimize clinical trial designs, and ultimately increase the likelihood of matching the right drug to the right patient.

Neumora has rapidly scaled its pipeline, which currently consists of seven clinical and preclinical neuroscience programs. Its most advanced product candidate is navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor (KOR) antagonist. Navacaprant is being developed for the treatment of moderate to severe major depressive disorder (MDD), a condition where many patients do not respond adequately to existing treatments. Neumora is initiating a pivotal Phase 3 program for navacaprant monotherapy and anticipates releasing topline results for its KOASTAL-1 study in the second half of 2024. The company expects to advance multiple other programs into clinical trials over the next 12 to 18 months, supporting numerous anticipated data readouts.

The primary market Neumora serves includes the vast population of patients suffering from brain diseases, which collectively affect over 1.5 billion individuals globally. This market represents a significant area of unmet medical need, particularly in conditions like MDD, where an estimated 85% of patients either do not receive pharmacological treatment or fail to achieve remission with first-line therapies. By focusing on novel mechanisms of action and a precision-guided development strategy, Neumora aims to provide new and more effective treatment options for patients who currently lack diverse and targeted therapeutic choices.

AI Analysis | Feedback

Neumora Therapeutics is like **Moderna, but for brain diseases**, using a data-driven 'precision medicine' approach to find specific treatments for complex neurological and psychiatric disorders.

Alternatively, think of Neumora Therapeutics as **a Loxo Oncology for brain diseases**, leveraging a 'precision medicine' strategy to develop targeted therapies for specific patient populations in neurological and psychiatric disorders.

AI Analysis | Feedback

  • Navacaprant (NMRA-140): A novel once-daily oral kappa opioid receptor (KOR) antagonist currently in a pivotal Phase 3 program for the treatment of major depressive disorder (MDD).
  • Six Clinical and Preclinical Neuroscience Programs: A pipeline of drug candidates targeting novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases.

AI Analysis | Feedback

Neumora Therapeutics (NMRA) is a clinical-stage biopharmaceutical company. Its primary focus is on the research and development of novel therapeutic candidates for brain diseases. As a clinical-stage company, Neumora Therapeutics is currently developing its drug candidates through various phases of clinical trials, such as the pivotal Phase 3 program for navacaprant (NMRA-140).

At this stage of development, Neumora Therapeutics does not have major customers in the traditional sense, as it is not yet commercializing or selling approved pharmaceutical products to other companies or individuals. Its "products" are investigational drug candidates that are undergoing clinical evaluation.

AI Analysis | Feedback

null

AI Analysis | Feedback

Paul L. Berns, Chief Executive Officer and Chairman
Paul L. Berns is the co-founder, Chief Executive Officer, and Chairman of Neumora Therapeutics. He is also a Managing Director with ARCH Venture Partners. Berns has a history of leadership roles, including serving as President, CEO, and Chairman of Anacor Pharmaceuticals, which was acquired by Pfizer in 2016. He also held the roles of President and CEO at Allos Therapeutics, acquired by Spectrum Pharmaceuticals in 2012, and President and CEO of Bone Care International, acquired by Genzyme Corporation in 2005. Berns co-founded and was Executive Chairman of Tenvie Therapeutics and Ollin Biosciences, and also co-founded and was Chairman of the Board for HI-Bio prior to its acquisition by Biogen in July 2024. Additionally, he was a co-founder and Lead Independent Director of Metsera Therapeutics before its acquisition by Pfizer in November 2025. His career includes senior management positions at Bristol-Myers Squibb from 1990 to 2000.

Michael Milligan, Chief Financial Officer
Michael Milligan is Neumora's Chief Financial Officer. He joined Neumora in December 2021 as Senior Vice President of Finance and Principal Accounting Officer and was instrumental in the company's successful IPO in 2023. Prior to Neumora, he served as Vice President of Finance and Corporate Controller at Y-Mabs Therapeutics, Inc. His experience also includes roles as Vice President of Finance and Corporate Controller at Acorda Therapeutics, Inc., Executive Vice President and Chief Financial Officer at New Haven Pharmaceuticals, Inc., and Vice President and Chief Accounting Officer at Shionogi, Inc. Milligan began his career in public accounting at KPMG LLP and Ernst & Young LLP. He is a Certified Public Accountant.

Joshua Pinto, Ph.D., President
Dr. Joshua Pinto currently serves as President of Neumora, a role he assumed after initially joining the company as Chief Financial Officer in June 2021. In his previous CFO role, he contributed to building Neumora's neuroscience pipeline through business development and played a key part in the company's fundraising strategy. Dr. Pinto's background also includes serving on the Board of Directors for Metsera, Inc. Earlier in his career, he worked as a healthcare investment banker and in global external R&D at Eli Lilly. He holds a Ph.D. in neuroscience and an MBA in finance from McMaster University.

Bill Aurora, Pharm.D., Chief Operating and Development Officer
Dr. Bill Aurora is the Chief Operating and Development Officer at Neumora, having joined the company in 2021 and held roles of increasing responsibility. Before joining Neumora, he was the Chief Scientific Affairs Officer at Dermira, Inc., which was acquired by Eli Lilly in 2020. His prior experience includes vice president roles in medical affairs at Neurocrine Biosciences (2015-2016) and global scientific affairs at Merck Research Laboratories (2014-2015). He also held various positions at Amgen from 2002 to 2014, including Vice President, Global Scientific Affairs, Global Development. Dr. Aurora is board-certified in psychiatric pharmacy practice.

John Reynders, Ph.D., Chief Data Sciences Officer
Dr. John Reynders serves as Neumora's Chief Data Sciences Officer, a role he assumed in 2020. He is an experienced data scientist with over two decades of experience in computational science and its integration into drug development. Prior to Neumora, he was Vice President of Data Science, Genomics and Bioinformatics at Alexion Pharmaceuticals. He was also the founding Chief Information Officer of Moderna Therapeutics and served as Head of Neuroscience Biomarkers and Integrative Solutions at Johnson & Johnson. His extensive career includes executive positions leading data sciences, informatics, and technology at AstraZeneca, Eli Lilly, and Celera.

AI Analysis | Feedback

The key risks to Neumora Therapeutics' business are:

  1. Clinical Trial Failures and Inability to Secure Regulatory Approval: As a clinical-stage biopharmaceutical company, Neumora's success heavily relies on its therapeutic candidates successfully progressing through clinical trials and ultimately receiving regulatory approval. The company is initiating a pivotal Phase 3 program for its most advanced product candidate, navacaprant, and anticipates releasing topline results in the second half of 2024. Failure to demonstrate efficacy and safety in these trials, or an inability to obtain regulatory approval for any of its pipeline programs, including navacaprant, would significantly impede its business prospects.

  2. Market Acceptance and Competition from Established Treatments: Even if Neumora's product candidates are approved, they face the challenge of gaining market acceptance and competing effectively against existing treatments. The background notes that markets for prevalent brain disorders, such as Major Depressive Disorder (MDD), have been dominated by single classes of drugs (e.g., serotonin-targeting antidepressants). While Neumora aims to address unmet needs with novel mechanisms, it must prove significant advantages over these entrenched standard-of-care options to capture market share.

AI Analysis | Feedback

null

AI Analysis | Feedback

Neumora Therapeutics' primary product candidate, navacaprant (NMRA-140), targets Major Depressive Disorder (MDD).

The addressable market for Major Depressive Disorder (MDD) treatment is substantial both globally and in the United States:

  • Globally, the major depressive disorder treatment market was approximately USD 12,000 million (USD 12 billion) in 2025, and it is projected to grow to USD 15,800 million (USD 15.8 billion) by 2035.
  • In the United States, the Major Depressive Disorder market size was approximately USD 5,600 million (USD 5.6 billion) in 2023, with an expected increase by 2034 at a Compound Annual Growth Rate (CAGR) of 4.8%.
  • Additionally, over 21 million adults in the United States are diagnosed with Major Depressive Disorder.

AI Analysis | Feedback

Neumora Therapeutics (NMRA) is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Its future revenue growth over the next 2-3 years is primarily anticipated to be driven by the advancement and potential commercialization of its diverse pipeline of neuroscience programs. Here are 3-5 expected drivers of future revenue growth for Neumora Therapeutics:
  1. Successful Advancement and Potential Approval of Navacaprant (NMRA-140) for Major Depressive Disorder (MDD): Navacaprant is Neumora's most advanced product candidate, a kappa opioid receptor (KOR) antagonist. Following adjustments to its pivotal Phase 3 program, the company anticipates a joint topline data readout for the KOASTAL-2 and KOASTAL-3 studies in the second quarter of 2026. Positive outcomes from these trials could lead to regulatory submissions and eventual market approval, with analysts projecting U.S. sales for navacaprant potentially reaching $750 million by 2028 and up to $3 billion at peak, if successfully commercialized.
  2. Clinical Progression of NMRA-215 for Obesity: Neumora has prioritized NMRA-215, a highly brain-penetrant NLRP3 inhibitor, for the treatment of obesity. The company plans to initiate a Phase 1 clinical program in the first half of 2026, with initial weight loss data expected around the end of 2026. Successful development in this area could open a significant market opportunity in the growing obesity treatment landscape.
  3. Advancement of the M4 Positive Allosteric Modulator (PAM) Franchise (NMRA-861 and NMRA-898) for Schizophrenia: Neumora is progressing Phase 1 clinical studies for NMRA-898 and NMRA-861, targeting schizophrenia. Initial clinical data for NMRA-861 is anticipated in the first quarter of 2026, with a comprehensive update on the M4 franchise expected in mid-2026. Successful development of these candidates could address substantial unmet needs in schizophrenia.
  4. Further Development of NMRA-511 for Alzheimer's Disease (AD) Agitation: NMRA-511, a vasopressin 1a receptor (V1aR) antagonist, demonstrated a clinically meaningful effect in its Phase 1b study for AD agitation, with positive results reported in January 2026. The progression of this program into later-stage clinical trials is expected and could contribute to future revenue generation by addressing a significant unmet medical need in AD agitation.

AI Analysis | Feedback

Inbound Investments and Share Issuances

  • Neumora Therapeutics raised over $600 million in venture financing prior to its initial public offering, including a Series A round and a $112 million Series B round in October 2022.
  • The company completed an initial public offering (IPO) in September 2023, raising approximately $250 million gross.
  • In May 2025, Neumora secured a $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025.

Outbound Investments

  • In 2020, Neumora acquired Abelian Therapeutics, BlackThorn Therapeutics, Syllable Life Sciences, Propellex Bio, and Alairion, which became wholly-owned subsidiaries.
  • In February 2022, the company licensed global rights to an M4 muscarinic receptor positive allosteric modulator program from Vanderbilt University.

Capital Expenditures

  • Neumora Therapeutics reported capital expenditures of approximately $1.3 million in 2024.
  • Capital expenditures were approximately $0.8 million in 2023 and $0.5 million in 2022.
  • These expenditures likely supported the company's research and development activities, including its therapeutic pipeline and the Precision Toolbox.

Peer Outperformance in Biotechnology

null
Share of Biotechnology constituents that NMRA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
9%
of 453 industry peers · -87.1% return
3Y
13%
of 399 industry peers · -97.2% return
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is NMRA's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology ← 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Neumora Therapeutics Earnings Notes12/16/2025
Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

NMRAAXSMNBIXJAZZACADDNLIMedian
NameNeumora .Axsome T.Neurocri.Jazz Pha.Acadia P.Denali T. 
Mkt Price0.33135.00164.87241.4218.3618.0076.68
Mkt Cap0.17.116.815.63.23.45.2
Rev LTM08653,7024,7181,202211,034
Op Inc LTM-187-1639101,134122-532-21
FCF LTM-167-831,0371,41486-4862
FCF 3Y Avg-187-1066901,25296-425-5
CFO LTM-167-821,0661,69298-4448
CFO 3Y Avg-187-1057261,416166-40231

Growth & Margins

NMRAAXSMNBIXJAZZACADDNLIMedian
NameNeumora .Axsome T.Neurocri.Jazz Pha.Acadia P.Denali T. 
Rev Chg LTM-54.2%38.0%13.5%14.8%-26.4%
Rev Chg 3Y Avg-57.2%27.8%7.6%24.9%-26.3%
Rev Chg Q-51.9%41.2%10.4%22.8%-32.0%
QoQ Delta Rev Chg LTM-11.4%9.7%2.5%5.6%493.3%9.7%
Op Inc Chg LTM22.3%16.1%64.4%149.9%29.6%2.9%25.9%
Op Inc Chg 3Y Avg-7.4%1.0%42.5%45.3%62.1%-67.8%21.8%
Op Mgn LTM--18.9%24.6%24.0%10.2%-2,488.1%10.2%
Op Mgn 3Y Avg--42.1%23.8%17.3%10.4%-13.9%
QoQ Delta Op Mgn LTM-4.7%0.7%4.6%2.6%12,570.0%4.6%
CFO/Rev LTM--9.5%28.8%35.9%8.1%-2,077.4%8.1%
CFO/Rev 3Y Avg--22.2%24.6%32.8%16.3%-20.4%
FCF/Rev LTM--9.5%28.0%30.0%7.2%-2,272.9%7.2%
FCF/Rev 3Y Avg--22.3%23.3%29.1%9.7%-16.5%

Valuation

NMRAAXSMNBIXJAZZACADDNLIMedian
NameNeumora .Axsome T.Neurocri.Jazz Pha.Acadia P.Denali T. 
Mkt Cap0.17.116.815.63.23.45.2
P/S-8.24.53.32.6158.54.5
P/Op Inc-0.3-43.318.413.825.9-6.46.7
P/EBIT-0.3-46.920.836.525.9-6.410.2
P/E-0.3-45.023.875.88.7-10.84.2
P/CFO-0.4-86.615.79.232.5-7.64.4
Total Yield-307.1%-2.2%4.2%1.3%11.5%-9.3%-0.4%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-76.3%-1.9%5.1%13.7%3.5%-12.2%0.8%
D/E0.90.00.00.40.00.00.0
Net D/E-0.5-0.0-0.00.2-0.3-0.1-0.1

Returns

NMRAAXSMNBIXJAZZACADDNLIMedian
NameNeumora .Axsome T.Neurocri.Jazz Pha.Acadia P.Denali T. 
1M Rtn-30.6%-14.1%21.5%14.8%-4.0%2.2%-0.9%
3M Rtn-79.9%-37.4%6.9%-4.6%-39.2%-26.0%-31.7%
6M Rtn-80.3%-40.4%6.8%1.7%-10.4%-0.6%-5.5%
12M Rtn-87.3%-7.3%14.8%41.9%-23.5%3.6%-1.8%
3Y Rtn-97.3%125.5%51.3%100.2%-19.6%-4.1%23.6%
1M Excs Rtn-26.5%-9.8%23.9%19.4%-3.7%3.3%-0.2%
3M Excs Rtn-76.2%-34.4%9.8%-0.5%-35.4%-26.2%-30.3%
6M Excs Rtn-81.1%-41.3%6.0%0.8%-11.2%-1.5%-6.4%
12M Excs Rtn-97.6%-13.4%3.7%61.0%-33.7%-6.9%-10.2%
3Y Excs Rtn-164.0%67.6%-13.7%32.7%-85.4%-57.0%-35.4%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil202220212020
Development of clinical and preclinical neuroscience programs that target novel mechanisms of action000
Total000


Net Income by Segment
$ Mil2025202420232022
Development of clinical and preclinical neuroscience programs that target novel mechanisms of action-237-244-236-131
Total-237-244-236-131


Assets by Segment
$ Mil2023202220212020
Development of clinical and preclinical neuroscience programs that target novel mechanisms of action496426429198
Total496426429198


Price Behavior

Price Behavior
Market Price$0.33 
Market Cap ($ Bil)0.1 
First Trading Date09/15/2023 
Distance from 52W High-90.7% 
   50 Days200 Days
DMA Price$0.56$1.69
DMA Trenddowndown
Distance from DMA-40.7%-80.2%
 3M1YR
Volatility133.3%131.6%
Downside Capture545.62226.50
Upside Capture-120.66-26.33
Correlation (S&P 500)16.3%8.1%
NMRA Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta-0.270.020.44-0.550.591.23
Up Beta-12.93-6.39-3.70-4.70-0.620.59
Down Beta-4.01-2.11-1.39-0.930.641.49
Up Capture-233%-244%-134%-94%-18%63%
Bmk +ve Days12182862130427
Stock +ve Days69184698348
Down Capture428%501%450%240%163%113%
Bmk -ve Days10253664121325
Stock -ve Days16334475144387

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NMRA
NMRA-87.5%131.6%-0.97-
Sector ETF (XLV)24.2%16.9%1.1021.2%
Equity (SPY)10.2%13.8%0.457.9%
Gold (GLD)-6.3%28.8%-0.237.1%
Commodities (DBC)31.6%21.3%1.18-13.9%
Real Estate (VNQ)10.0%14.2%0.4217.4%
Bitcoin (BTCUSD)-31.4%43.7%-0.752.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NMRA
NMRA-55.3%114.0%-0.45-
Sector ETF (XLV)8.6%15.4%0.3618.2%
Equity (SPY)10.9%17.3%0.4616.8%
Gold (GLD)15.5%19.2%0.654.1%
Commodities (DBC)7.1%19.6%0.25-3.6%
Real Estate (VNQ)0.9%19.0%-0.0617.1%
Bitcoin (BTCUSD)-0.6%51.4%0.176.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NMRA
NMRA-33.1%114.0%-0.45-
Sector ETF (XLV)12.4%16.8%0.6118.2%
Equity (SPY)14.9%18.0%0.7016.8%
Gold (GLD)11.2%16.6%0.554.1%
Commodities (DBC)7.4%18.2%0.32-3.6%
Real Estate (VNQ)5.8%20.7%0.2417.1%
Bitcoin (BTCUSD)57.2%66.3%0.976.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity7.0 Mil
Short Interest: % Change Since 1015202624.2%
Average Daily Volume1.4 Mil
Days-to-Cover Short Interest5.1 days
Basic Shares Quantity187.9 Mil
Short % of Basic Shares3.7%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/14/2026-7.5%-12.4%-42.2%
5/7/2026-16.7%-23.6%-30.0%
11/6/2025-1.5%9.2%-16.4%
8/6/20253.8%-1.9%5.7%
5/12/2025-1.9%-0.3%33.1%
3/3/2025-9.9%-4.5%-35.9%
11/12/2024-17.1%-27.9%-22.9%
8/6/20240.3%-6.7%-8.1%
...
SUMMARY STATS   
# Positive514
# Negative6107
Median Positive3.3%9.2%10.6%
Median Negative-8.7%-5.6%-22.9%
Max Positive4.9%9.2%33.1%
Max Negative-17.1%-27.9%-42.2%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/14/2026-7.5%-12.4%-42.2%
5/7/2026-16.7%-23.6%-30.0%
11/6/2025-1.5%9.2%-16.4%
8/6/20253.8%-1.9%5.7%
5/12/2025-1.9%-0.3%33.1%
3/3/2025-9.9%-4.5%-35.9%
11/12/2024-17.1%-27.9%-22.9%
8/6/20240.3%-6.7%-8.1%
5/7/20244.9%-4.2%6.8%
3/7/20243.3%-19.5%-22.1%
11/1/20231.2%-1.5%14.3%
SUMMARY STATS   
# Positive514
# Negative6107
Median Positive3.3%9.2%10.6%
Median Negative-8.7%-5.6%-22.9%
Max Positive4.9%9.2%33.1%
Max Negative-17.1%-27.9%-42.2%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/16/202610-Q
06/30/202608/14/202610-Q
03/31/202605/07/202610-Q
12/31/202503/30/202610-K
09/30/202511/06/202510-Q
06/30/202508/06/202510-Q
03/31/202505/12/202510-Q
12/31/202403/03/202510-K
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202303/07/202410-K
09/30/202311/01/202310-Q
06/30/202309/18/2023424B4
06/30/202209/02/2022DRS/A
03/31/202206/10/2022DRS/A
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/16/202610-Q
06/30/202608/14/202610-Q
03/31/202605/07/202610-Q
12/31/202503/30/202610-K
09/30/202511/06/202510-Q
06/30/202508/06/202510-Q
03/31/202505/12/202510-Q
12/31/202403/03/202510-K
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202405/07/202410-Q
12/31/202303/07/202410-K
09/30/202311/01/202310-Q
06/30/202309/18/2023424B4
06/30/202209/02/2022DRS/A
03/31/202206/10/2022DRS/A
09/30/202102/14/2022DRS/A

Insider Activity

Updated 8/21/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Aurora, Daljit SinghSee RemarksDirectSell82120261.5920,55332,78077,751Form
2Aurora, Daljit SinghSee RemarksSee footnoteSell82120261.6021,055  Form
3Aurora, Daljit SinghSee RemarksDirectSell82120261.5167,741102,58773,827Form
4Aurora, Daljit SinghSee RemarksSee footnoteSell82120261.5166,711  Form
5Aurora, Daljit SinghSee RemarksDirectSell81920261.6531,00051,02980,247Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Aurora, Daljit SinghSee RemarksDirectSell82120261.5920,55332,78077,751Form
2Aurora, Daljit SinghSee RemarksSee footnoteSell82120261.6021,055  Form
3Aurora, Daljit SinghSee RemarksDirectSell82120261.5167,741102,58773,827Form
4Aurora, Daljit SinghSee RemarksSee footnoteSell82120261.5166,711  Form
5Aurora, Daljit SinghSee RemarksDirectSell81920261.6531,00051,02980,247Form
6Aurora, Daljit SinghSee RemarksSee footnoteSell81920261.6530,918  Form
7Aurora, Daljit SinghSee RemarksDirectSell81920261.5834,16254,13777,254Form
8Aurora, Daljit SinghSee RemarksSee footnoteSell81920261.5934,987  Form
9Aurora, Daljit SinghSee RemarksDirectSell81920261.5091,690137,35273,028Form
10Aurora, Daljit SinghSee RemarksSee footnoteSell81920261.5055,016  Form
11Aurora, Daljit SinghSee RemarksDirectSell21920263.566,16521,917294,247Form
12Pinto, JoshuaPresidentDirectSell21920263.545,96721,093204,263Form
13Berns, Paul LSee RemarksDirectSell21920263.519,81934,45925,952,662Form
14Milligan, Michael LeeSee RemarksDirectSell21920263.561,4365,11974,986Form
15Aurora, Daljit SinghSee RemarksSee footnoteSell111320252.68114,703  Form
16Burow, Kristina ARCH Venture Fund XII, L.P.Buy102920252.611,915,7004,999,97715,782,427Form
17Arch, Venture Partners Xii, Llc ARCH Venture Fund XII, L.P.Buy102920252.611,915,7004,999,97715,782,427Form
18Arch, Venture Partners X, Llc ARCH Venture Fund XII, L.P.Buy102920252.611,915,7004,999,97715,782,427Form

Investor Activity (13F)

Updated Nov 18, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
MIC Capital Management UK LLP$8.7 Mil2.5%18Hold13F
Softbank Group Corp.$11.9 Mil0.1%31TRIM -5.3%13F
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST$6.5 Mil0.1%21Hold13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Softbank Group Corp.$11.9 Mil0.1%31TRIM -5.3%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Softbank Group Corp.$11.9 Mil0.1%31TRIM -5.3%13F
MIC Capital Management UK LLP$8.7 Mil2.5%18Hold13F
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST$6.5 Mil0.1%21Hold13F
Core Cache Last Updated: 11/17/2026